Search

everythinglearnresearchcommunity

for

Search:↓

A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.

PCOS is linked to low-grade chronic inflammation.

A new minoxidil-like substance, triaminodil, was found in an illegal hair growth supplement.

Some drugs linked to growth hormones may increase the chance of hair loss in women.

The new minoxidil emulgel with marine-based polymers shows effective controlled drug release for hair growth treatment.

Polygonum multiflorum is used for health benefits but may cause liver issues.

Certain factors like being female, having high cholesterol, using Medicaid, and previous non-biologic treatments increase the risk of multiple biologic failures in psoriasis patients.

α-MSH may help treat skin inflammation and fibrosis.

GLP-1 receptor agonists can help manage PCOS metabolism but need careful use before conception.

Topical Vorinostat shows promise for treating alopecia areata by promoting hair regrowth.

Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.

Elagolix did not effectively treat polycystic ovary syndrome.

Clofazimine may be effective for treating ashy dermatosis.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

A protein called PCBP2 controls the production of a hair growth protein by interacting with its genetic message and is linked to hair loss when this control is disrupted.

Clobetasol propionate 0.05% is more effective for hair re-growth in alopecia areata than tacrolimus 0.1%.

Folliculotropic mycosis fungoides has unique molecular features and cell interactions that could guide targeted therapy.

The combination therapy may be more effective for mild alopecia areata, especially in patients with allergies.

New patents show progress in developing drugs targeting the Wnt pathway for diseases like cancer and hair loss.

Tacrolimus is a better option than cyclosporine due to fewer side effects.

Customized dermatological treatments effectively address gaps in standard products, especially for complex cases.

Multimodal therapy effectively improves early-stage hair loss.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

Leflunomide is effective for rheumatoid arthritis but has significant side effects.

Modified frameworks with stearic acid enhance drug delivery and promote hair growth.

Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.